General Information of This Drug (ID: DMDOZPU)

Drug Name
PK 11195   DMDOZPU
Synonyms
1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide; 85532-75-8; PK-11195; PK11195; RP 52028; BRN 4264456; CHEBI:73290; N-sec-butyl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; N-(butan-2-yl)-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-; SMR000058427; SR-01000076240; Biomol-NT_000287; AC1L1B9T; DSSTox_RID_79625; Interferon alfa (IFN-alpha)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
PK 11195 + Ruxolitinib DC23TN8 Ruxolitinib T-cell leukemia/lymphoma (Cell Line: ED-40515) [2]
------------------------------------------------------------------------------------

References

1 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.